Compare Stocks → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AVRONASDAQ:AVTXNASDAQ:CBAYNASDAQ:FIRENASDAQ:FTRP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVROAVROBIO$1.28+1.6%$1.30$0.57▼$1.70$57.42M1.24317,367 shs104,197 shsAVTXAvalo Therapeutics$21.75+357.9%$5.00$3.95▼$1,130.40$1.96M0.69611,754 shs31.83 million shsCBAYCymaBay Therapeutics$32.48+0.0%$29.62$7.26▼$32.50$3.73B0.324.11 million shs8.36 million shsFIRE(FIRE)$0.00$0.00▼$0.00N/AN/AN/AN/AFTRPField Trip Health$1.12$2.76$0.71▼$6.41$65.20MN/A214,681 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVROAVROBIO0.00%-1.56%-3.08%-11.27%+20.00%AVTXAvalo Therapeutics-0.21%+6.26%+9.20%-59.85%-98.86%CBAYCymaBay Therapeutics0.00%+0.03%+0.62%+35.39%+268.25%FIRE(FIRE)0.00%0.00%0.00%0.00%0.00%FTRPField Trip Health0.00%0.00%0.00%0.00%+64.68%AI healthcare stock poised for 36,996% growth? (Ad)Buy Alert Issued For AI Small Cap Our last two AI stocks jumped 150% and 130%... But we just issued a brand new "buy alert" for a new one...Get the name of the stock here...MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVROAVROBIO2.1214 of 5 stars3.03.00.00.03.31.70.6AVTXAvalo Therapeutics0.3651 of 5 stars0.02.00.00.02.91.70.6CBAYCymaBay Therapeutics3.744 of 5 stars2.04.00.04.72.02.50.6FIRE(FIRE)N/AN/AN/AN/AN/AN/AN/AN/AFTRPField Trip HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVROAVROBIO2.00Hold$2.0056.25% UpsideAVTXAvalo Therapeutics2.00HoldN/AN/ACBAYCymaBay Therapeutics2.08Hold$28.65-11.79% DownsideFIRE(FIRE)N/AN/AN/AN/AFTRPField Trip HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest FTRP, CBAY, AVRO, FIRE, and AVTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails2/29/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$32.502/20/2024CBAYCymaBay TherapeuticsSVB LeerinkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$32.502/14/2024CBAYCymaBay TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform2/14/2024CBAYCymaBay TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral$33.00 ➝ $32.502/14/2024CBAYCymaBay TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$25.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral2/13/2024CBAYCymaBay TherapeuticsJonestradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold2/13/2024CBAYCymaBay TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$32.502/13/2024CBAYCymaBay TherapeuticsB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$29.00 ➝ $32.502/13/2024CBAYCymaBay TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVROAVROBION/AN/A$0.29 per share4.40$2.13 per shareN/AAVTXAvalo Therapeutics$18.05M0.11N/AN/A($275.57) per share-0.08CBAYCymaBay Therapeutics$31.07M119.92N/AN/A$2.58 per share12.59FIRE(FIRE)N/AN/AN/AN/AN/AN/AFTRPField Trip Health$3.88M16.80N/AN/A$0.92 per share1.22Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVROAVROBIO$12.16M-$0.10N/AN/AN/AN/A-74.86%-65.11%3/28/2024 (Estimated)AVTXAvalo Therapeutics-$41.66M-$616.67N/AN/AN/A-1,475.02%N/A-107.83%4/3/2024 (Estimated)CBAYCymaBay Therapeutics-$105.37M-$0.97N/AN/AN/AN/A-50.72%-31.04%5/20/2024 (Estimated)FIRE(FIRE)N/AN/A0.00N/AN/AN/AN/AN/AN/AFTRPField Trip Health-$43.63M-$0.77N/AN/AN/A-1,125.12%-62.71%-47.29%N/ALatest FTRP, CBAY, AVRO, FIRE, and AVTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/29/2024N/AAVTXAvalo TherapeuticsN/A-$4.80-$4.80N/AN/AN/A2/28/2024Q4 2023CBAYCymaBay Therapeutics-$0.31-$0.35-$0.04-$0.35$0.42 million$0.06 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVROAVROBION/AN/AN/AN/AN/AAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACBAYCymaBay TherapeuticsN/AN/AN/AN/AN/AFIRE(FIRE)N/AN/AN/AN/AN/AFTRPField Trip HealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVROAVROBION/A15.7815.78AVTXAvalo TherapeuticsN/A2.112.11CBAYCymaBay TherapeuticsN/A10.9610.96FIRE(FIRE)N/AN/AN/AFTRPField Trip Health0.408.208.20OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVROAVROBIO62.63%AVTXAvalo Therapeutics87.06%CBAYCymaBay Therapeutics95.03%FIRE(FIRE)N/AFTRPField Trip Health16.84%Insider OwnershipCompanyInsider OwnershipAVROAVROBIO9.20%AVTXAvalo Therapeutics0.20%CBAYCymaBay Therapeutics7.00%FIRE(FIRE)N/AFTRPField Trip HealthN/AMiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAVROAVROBIO1344.86 million40.73 millionOptionableAVTXAvalo Therapeutics2090,00085,000Not OptionableCBAYCymaBay Therapeutics101114.72 million106.69 millionOptionableFIRE(FIRE)N/AN/AN/ANot OptionableFTRPField Trip Health10458.22 millionN/ANot OptionableFTRP, CBAY, AVRO, FIRE, and AVTX HeadlinesSourceHeadlineField Trip to the Hill Immerses Students in Career Areawku.edu - March 11 at 5:30 PMYouth Field Trip Support Vonlunteerrescue.org - July 9 at 9:18 AMWhat Is A Single Trip Travel Insurance?forbes.com - July 1 at 2:07 PMB.C. school reverses decision to exclude 'devastated' girl with disabilities from tripca.style.yahoo.com - June 26 at 8:59 AMField Trip! Hackaday Visits Adafruit Industrieshackaday.com - May 30 at 8:50 AMIndiana offering teacher grants for state park field tripsnwitimes.com - May 19 at 8:17 AMBison the focus of special field trip for Bow Valley studentscbc.ca - May 16 at 8:02 AMHK students' first field trips to mainland set for April; over 400 schools sign upglobaltimes.cn - March 14 at 11:36 PM'The best of Wisconsin's natural world': NRF field trips are back for the 30th yearjsonline.com - March 11 at 9:34 PMField Trip Behind the Scenes at Dallas ISD Production Studios Meant to Expand Students' Mindsnbcdfw.com - March 11 at 9:34 PMJohnson City teachers study programming, auto mechanics during field tripwjhl.com - February 27 at 9:54 PMField Trip Health (FTHWF)nasdaq.com - February 27 at 9:54 PMThe ‘must-do’ trips everyone should take before they dienypost.com - February 26 at 8:04 PMField tripslse.ac.uk - February 25 at 5:01 PMTravel: A field trip that’s pure luxury in a shepherd’s hut in Romney Marshpeterboroughtoday.co.uk - October 28 at 2:14 PMField Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q1 2023 Results - Earnings Call Transcriptseekingalpha.com - August 16 at 3:33 PMReunion Neuroscience Inc. to Commence Trading on the Toronto Stock Exchange on August 17, 2022finance.yahoo.com - August 16 at 3:33 PMReunion Neuroscience Inc. (Formerly Field Trip Health Ltd.) Reports Fiscal First Quarter 2023 Financial Results, Completed Corporate Reorganization on August 11, 2022finance.yahoo.com - August 16 at 10:32 AMField Trip Health Ltd.: Field Trip Health & Wellness Ltd. Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financingfinanznachrichten.de - August 12 at 6:30 AMField Trip Health & Wellness Ltd. Announces Closing of Plan of Arrangement and $19.9 Million Private Placement Financingfinanznachrichten.de - August 12 at 6:30 AMHere's Why We're A Bit Worried About Field Trip Health's (TSE:FTRP) Cash Burn Situationfinance.yahoo.com - July 29 at 11:27 AMIIROC Trading Halt - FTRP.WTfinance.yahoo.com - July 5 at 5:00 PMField Trip Shares Fiscal Q4 And Full Year 2022 Results & Update On Court-Approved Corporate Reorganizationbenzinga.com - June 30 at 11:47 PMField Trip Health Ltd. (FTRP) CEO Joseph Del Moral on Q4 2022 Results - Earnings Call Transcriptseekingalpha.com - June 30 at 6:46 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAVROBIONASDAQ:AVROAVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Avalo TherapeuticsNASDAQ:AVTXAvalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein. It also develops AVTX-803, a L-fucose monosaccharide therapy for treatment of Leukocyte Adhesion Deficiency Type II. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.CymaBay TherapeuticsNASDAQ:CBAYCymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.(FIRE)NASDAQ:FIRESourcefire, Inc. (Sourcefire) is engaged in the business of delivering intelligent cybersecurity technologies. The Company provides a portfolio of solutions that enables commercial enterprises and government agencies worldwide to manage and minimize cybersecurity risks. Sourcefire provides customers with Agile Security that consists of hardware with embedded software, software and cloud-based solutions. It sells its solutions to a customer base that includes Global 2000 companies, global enterprises, the United States and international government agencies, and small and mid-size businesses. During the year ended December 31, 2012, it generated approximately 67% of the Company's revenue from customers in the United States, and 33% of the Company's revenue from customers outside of the United States. As of December 31, 2012, its product revenue and services revenue represented 61% and 39% of its total revenue, respectively.Field Trip HealthNASDAQ:FTRPField Trip Health Ltd. engages in the development and delivery of psychedelic- assisted therapies in North America. The company operates Field Trip Health Centres that provide psychedelic therapies; offers Field Trip Digital apps; operates Field Trip Discovery, a drug development division that develops the next generation of psychedelic molecules; and provides ketamine-assisted therapy for the treatment of depression, anxiety, addiction, and other conditions. Field Trip Health Ltd. was founded in 2008 and is headquartered in Toronto, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.